The Heidelberg, Germany, based venture capital firm EMBL Ventures announced Dec. 7 it had raised €40 million ($55 million) in a first closing for its second fund, EMBL Technology II (ETF II).
It is the second boost the European biotech community has received this week, after the UK government said it would spend £180 million ($280 million) on a biomedical catalyst fund...